# Tuning peptide specifities for T cell tolerance in Type 1 diabetes

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $442,995

## Abstract

Project Summary/Abstract
 Type 1 Diabetes (T1D) is a classical T-cell mediated autoimmune disease and substantial data implicates
insulin as a dominant autoantigen in T1D disease. In the NOD mouse model of T1D, notable studies have shown
that mice lacking native insulin expression, but with an altered insulin sequence to maintain blood glucose levels,
are completely protected from insulitis and diabetes. Growing evidence also indicates that insulin peptide binding
and orientation within MHC Class II (peptide register) is important in determining the strength of interaction and
recognition by autoreactive T cells. In collaboration with the Kappler lab, we have uncovered an unusual peptide
binding characteristic of the dominant insulin epitope InsB:9-23. The majority of InsB:9-23-specific CD4+ T cells
in the periphery recognize insulin bound in this unusual register 3, and by knocking in a single amino acid
variation (R to E) into just one copy of the insulin gene in NOD mice (Ins2EE/+), the mice are completely protected
against diabetes.
 The development of a “super agonist” version of the insulin dominant epitopes allows us to address several
key questions surrounding the biochemical pathways of peptide generation, presentation by MHC molecules,
and recognitions by auto-reactive pathogenic T cells. Do mutations of the major epitope in the insulin gene allow
CD4+ T effectors or Treg cells specific for these alternative epitopes to develop? Are mimotopes of these
pathogenic epitopes capable of dramatically altering disease outcomes? Are we able to fine tune these epitopes
to alter tolerance mechanisms to shift from deletion to Treg induction? Recent work in our lab has focused on
the identification of the insulin-specific repertoire on key mouse backgrounds, and we plan to utilize these tools
and well-characterized mouse models to examine the effects of altering insulin expression, thymically and
extrathymically. These tools as well as our experience with the generation of numerous TCR-transgenic mouse
lines will allow us to address these questions in the context of T1D.
 Thus, we hypothesize that alterations to epitope presentation and TCR affinity drive the tunning of
the TCR repertoire towards tolerance and away from self-reactivity. Using Insulin as a model antigen, we
propose to test our hypothesis through the following specific aims:
 Aim 1: Define the role of central tolerance upon the deletion of insulin-reactive clones
 Aim 2: Characterize the effects of peripheral tolerance on insulin-reactive T cells
 Aim 3: Explore mechanisms of dominate tolerance to understand the potential for translation into
 therapeutic treatments for T1D
 Through these experiments, we hope to gain a nuanced understanding of how changes in insulin epitopes and
antigenicity drive the pathogenesis of diabetes and identify targets for future immune modulation and
 therapeutic intervention for T1D treatment and prevention.

## Key facts

- **NIH application ID:** 10832019
- **Project number:** 5R01DK133443-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Mark S Anderson
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $442,995
- **Award type:** 5
- **Project period:** 2022-06-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10832019

## Citation

> US National Institutes of Health, RePORTER application 10832019, Tuning peptide specifities for T cell tolerance in Type 1 diabetes (5R01DK133443-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10832019. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*